{"ticker": {"uuid": "1c42d613-c405-45d7-9f43-f2050c317cb4", "symbol": "REGN", "name": "Regeneron Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?", "summary": "Regeneron Pharmaceuticals (REGN) recently experienced a clinical trial setback, causing its stock price to decline by almost 13% over 90 days, despite a 20.39% 1-year return. Analysts still view the stock as undervalued, with a fair value target of $833.31 against a current price", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-stumbled-in-a-trial-setback-i", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:54:59", "published_display": "15 Jul 2026 12:54", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "Vertex Pharmaceuticals (VRTX) is acquiring Crinetics Pharmaceuticals in a US$10 billion all-cash transaction, marking its entry into adrenal disease therapeutics. This acquisition includes atumelnant, a late-stage clinical drug candidate for congenital adrenal hyperplasia. The de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-vrtx-is-buying-crinetics-for-10-billion-to-enter-adre", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:51:29", "published_display": "15 Jul 2026 12:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease", "summary": "Alnylam Pharmaceuticals presented significant advancements in its neuroscience portfolio at AAIC 2026, focusing on RNAi therapeutics for neurological diseases. Key announcements include the initiation of a global Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer'", "url": "https://uk.finance.yahoo.com/news/alnylam-highlights-progress-neuroscience-programs-073000834.html", "source_name": "Market source", "published_at": "2026-07-15T07:45:34", "published_display": "15 Jul 2026 07:45", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQY3IwRDM1SGNON0J2T1R2aWRwLTFIV2h6QUt1R2ppbVA3Z1h5dXNuYWZxeHJ0dmJ0THBoVFJoVG1XTW5VNmRYSjAzcXlPVjdIMnA3dkt6ZVU2a3pvUGdyQmtwLWJKRUN5OWdEUVoyNGU4MndFMHdhUUE2RFVmZkFtMEpJdFlrdXlsSWkzVXBCTnZpUVh4VHBhRF9DY1RLSHVacHZSdmRUSmlUSjVIUVBLQ2xVQkduemM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:45:06+00:00", "published_display": "15 Jul 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day", "summary": "Regeneron Pharmaceuticals Inc. (REGN) saw its stock slide by 1.05% to $656.12, marking its third consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) rose 0.38% and the Dow Jones Industrial Average (DJIA) ros", "url": "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-outperforms-competitors-despite-losses-on-the-day-f2cdf7b8-58b39835bef2?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-14T23:08:47", "published_display": "14 Jul 2026 23:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab", "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that its medication dupilumab received FDA orphan drug designation, a status granted to drugs for rare diseases that offers benefits like tax credits and market exclusivity. This designation is a significant milestone, enhan", "url": "https://www.gurufocus.com/news/8958647/regeneron-regn-receives-fda-orphan-drug-designation-for-dupilumab", "source_name": "GuruFocus", "published_at": "2026-07-14T21:56:02", "published_display": "14 Jul 2026 21:56", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron stock holds firm as the focus shifts to the pipeline", "summary": "Regeneron Pharmaceuticals, Inc. (REGN) is a Nasdaq-listed biotech company focusing on a diversified drug portfolio and a late-stage pipeline. The company's business model generates revenue from marketed medicines and collaboration agreements, with its research platform centered o", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/regeneron-stock-holds-firm-as-the-focus-shifts-to-the-pipeline/69763731", "source_name": "Ad Hoc News", "published_at": "2026-07-14T06:14:19", "published_display": "14 Jul 2026 06:14", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes Regeneron Pharmaceuticals' (REGN) presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key highlights include strong double-digit growth in Q1 driven by core franchises, a robust pipeline with approximately 50 candidates, and", "url": "https://quartr.com/events/regeneron-pharmaceuticals-regn-goldman-sachs-47th-annual-global-healthcare-conference-2026_3g9vFpjs", "source_name": "Quartr", "published_at": "2026-07-14T05:38:59", "published_display": "14 Jul 2026 05:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) A Bargain On Its Expanded CASGEVY Approval?", "summary": "Vertex Pharmaceuticals (VRTX) recently received expanded US approval for its gene therapy CASGEVY for children with sickle cell disease or beta thalassemia, influencing its stock performance. Despite a recent dip, the stock maintains long-term momentum and trades significantly be", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-a-bargain-on-its-expanded-cas", "source_name": "Simply Wall Street", "published_at": "2026-07-14T00:56:20", "published_display": "14 Jul 2026 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod \u2014 Drug Pricing Deal With White House To Be Announced Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOVVpIY2VFTkR2Mm42emFvcGxFRjNqMjh0bzZpak1SSmRFVGFNZllON2xtLW41ek4xWVNFYmhHVktjSGZua3A4UWpHb0lXS296ek9LbUhYQlM4YmdiQVpVVEN2aEhJUEF3OVVOcTRIRGpXZUFldWpiNXJPRnFUZy14TjhRa1g1ZWJ0LWpzRm0zTGEzeVpJUElDVzBVOUFGSnMySkxjeTQ0V3lGU2J0ZVU3bGZRUWJyX2VORkN1VlBNYkJYZXVua3Zv?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T22:36:29+00:00", "published_display": "13 Jul 2026 22:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron\u2019s (REGN) Investment Narrative?", "summary": "Regeneron Pharmaceuticals (REGN) recently experienced a setback with disappointing clinical trial results, raising concerns about its near-term pipeline productivity despite strong sales of Dupixent and Eylea and active share repurchases. This contrast has led to a shift in inves", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/did-disappointing-trial-data-amid-strong-dupixent-and-eylea/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-13T21:38:55", "published_display": "13 Jul 2026 21:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case.", "summary": "Incyte presents a clearer path for biotech investors seeking growth compared to Regeneron. While Regeneron manages complexities with its massive blockbusters and relies on pipeline faith, Incyte has raised its full-year guidance and is showing accelerating growth outside its main", "url": "https://www.trefis.com/stock/regn/articles/606839/own-regeneron-for-biotech-growth-incyte-is-making-its-case/2026-07-13", "source_name": "Trefis", "published_at": "2026-07-13T17:37:03", "published_display": "13 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cantor Fitzgerald reiterates Overweight on Regeneron stock", "summary": "Cantor Fitzgerald reiterated an Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750.00. The firm discussed the potential of Regeneron's pozelimab/cemdisiran treatment for retinal conditions, noting cautious optimism from a key opinion leader about its ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-regeneron-stock-93CH-4788459", "source_name": "Investing.com", "published_at": "2026-07-13T12:38:04", "published_display": "13 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Regeneron stock By Investing.com", "summary": "Cantor Fitzgerald has reaffirmed its Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750, despite previously lowering it from $785 due to concerns about Eylea HD/SD and Dupixent performance. The firm's positive outlook is based on Regeneron's pozelimab", "url": "https://ca.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-regeneron-stock-93CH-4731128", "source_name": "Investing.com Canada", "published_at": "2026-07-13T12:35:51", "published_display": "13 Jul 2026 12:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2", "summary": "Longleaf Partners Fund's Q2 2026 investor letter noted that Regeneron Pharmaceuticals (REGN) was a detractor due to disappointing trial results for one of its pipeline drugs. While Dupixent's performance exceeded expectations and Eylea stabilized, the company's \"one out of three\"", "url": "https://finance.yahoo.com/healthcare/articles/disappointing-trial-results-hurt-regeneron-143335859.html", "source_name": "Market source", "published_at": "2026-07-13T10:33:00", "published_display": "13 Jul 2026 10:33", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Cites Medtronic Ruling In Amgen Bundling Case", "summary": "Regeneron has invoked a recent Medtronic ruling in a California federal court to bolster its $407 million victory against Amgen. This action was taken in a Delaware federal court, where Regeneron is seeking to preserve its win in a case concerning the bundling of cholesterol drug", "url": "https://www.law360.com/healthcare-authority/deals-corporate-governance/articles/2498786/regeneron-cites-medtronic-ruling-in-amgen-bundling-case", "source_name": "Law360", "published_at": "2026-07-10T01:09:37", "published_display": "10 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGN Maintained by Piper Sandler -- Price Target Lowered to $854", "summary": "Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals (REGN) but slightly lowered its price target from $855 to $854. Despite this minor adjustment, the company is considered 26.5% undervalued according to GuruFocus's GF Value\u2122 and holds a strong GF Score", "url": "https://www.gurufocus.com/news/8951888/regn-maintained-by-piper-sandler-price-target-lowered-to-854", "source_name": "GuruFocus", "published_at": "2026-07-09T16:22:34", "published_display": "09 Jul 2026 16:22", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855", "summary": "Piper Sandler has slightly decreased its price target for Regeneron Pharmaceuticals (REGN) from $855 to $854. The firm maintained an Overweight rating on the stock. This adjustment reflects a minor change in Piper Sandler's valuation outlook for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/72711738/piper-sandler-adjusts-price-target-on-regeneron-pharmaceuticals-to-854", "source_name": "Moomoo", "published_at": "2026-07-09T15:38:38", "published_display": "09 Jul 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730", "summary": "Morgan Stanley has reiterated its Hold rating on Regeneron Pharmaceuticals (REGN.US) but decided to lower its target price for the stock to $730. This adjustment in the target price suggests a revised outlook by the analyst firm on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72655814/morgan-stanley-maintains-regeneron-pharmaceuticals-regnus-with-hold-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-09T08:38:55", "published_display": "09 Jul 2026 08:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating", "summary": "Morgan Stanley has lowered its price target for Regeneron Pharmaceuticals (NASDAQ: REGN) to $730 from $788, while maintaining an Equalweight rating on the stock. This adjustment comes after a review of the company's financial outlook.", "url": "https://www.moomoo.com/news/post/72642560/morgan-stanley-adjusts-price-target-regeneron-pharmaceuticals-to-730-from", "source_name": "Moomoo", "published_at": "2026-07-09T03:08:40", "published_display": "09 Jul 2026 03:08", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGN Maintained by Morgan Stanley -- Price Target Lowered to $73", "summary": "Morgan Stanley has maintained an Equal-Weight rating on Regeneron Pharmaceuticals (REGN) but lowered its price target from $788 to $730, citing a cautious outlook. Despite this, GuruFocus indicates REGN is undervalued by 26.5% with a strong GF Score\u2122 of 78/100, driven by excellen", "url": "https://www.gurufocus.com/news/8950280/regn-maintained-by-morgan-stanley-price-target-lowered-to-730", "source_name": "GuruFocus", "published_at": "2026-07-08T22:45:37", "published_display": "08 Jul 2026 22:45", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors", "summary": "Regeneron Pharmaceuticals Inc. (REGN) stock declined by 1.97% to $662.88 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also fell. The company's stock closed 19.27% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-underperforms-wednesday-when-compared-to-competitors-e2608ad2-a4264797bd51", "source_name": "MarketWatch", "published_at": "2026-07-08T20:43:00", "published_display": "08 Jul 2026 20:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar", "summary": "Regeneron Pharmaceuticals Inc. successfully moved to dismiss Amgen Inc.'s fraud-based defenses and certain antitrust claims concerning proposed Eylea biosimilars. However, a federal judge allowed Amgen to continue arguing that Regeneron delayed too long in pursuing a specific pat", "url": "https://news.bloomberglaw.com/ip-law/regeneron-narrows-amgen-challenges-in-case-over-eylea-biosimilar", "source_name": "Bloomberg Law News", "published_at": "2026-07-08T15:59:00", "published_display": "08 Jul 2026 15:59", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals balances growth prospects as a major biotech player. The company continues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQSWdtUjBMUTduUTZHSFBuVVQwcnRRR3h2VWEtVHZ0NEpPUVZBZFdfd3FMd2Z5bDB3dnRpdzdtMnFlTkZyMEx2OFRwSXNRRUwyV2pVMnVzbW4yOHFBdWphZnBBQnNqVWdGMFRZVDJXV2NZQUpxUjJ5S0U0MlpxelBzV1BqcEFGdnZ3SEJjS3cxbndFbjBqNVNGb2pheUoxMjNaajlJQnoxbU5faERzLV9JT1FkYlpUUnlHN1ZFdWRCVTF2TkRMWmd6YQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaGstaFdQa3pfYzJ1SFBhZ3ltbUxXS0IxVkhvc2xCTVFrdDU5dVVZaUZDZnpnNm85Y1NrVFhDc0xETEYzMkZNNmNzMHBDdTdvUDlQdklibFN4N2hwLTAySXVHUkRYcFJOWm55S3dwSERMWlNVTE1SVHAtWWVoZUYweHlvZ2IwM2FZQ1R5b3NmTFQwdUpuc09tZ0lTR0FDVWo1LVVB?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals profile and stock context for US investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPaFVuYnJ4MXRVaXIyWHUxdnBPRGljVDZUa1VKb0t6M1U3MmM4SkFoRURQMHRCS2M3VmhZTkdTMVpNM25oNklmQS0tYnpKRlMtY2drclIxQ01Kdkx3NEREM0hQZ2dCNFZMaGkwTlk2c2JpU00xZEFZVWdVaGw5QnA5MERvUEZjYU9DZ0dBc0RrN1JMa1RxQ09sSC1QbXJTQUlfVm1Zc19FOEFkbkJYZXk5b05lcm4wNHpzSlM1VElMb3Z0QjNncXc?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:37:25+00:00", "published_display": "07 Jul 2026 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOSFAzZjROeDlMbllNcVBfbmIwMlpNUXdhU2dCaTZUa2VVODZZeW5UeDZHcW5HdFdzak00Xzk2RF95UnpfazM4N0NvY3FCTThCSVZqblJvenloN1BKRE1NcGNQenVzcnVZU2ZtclUwYjg3TEFncXI1OFdKSm40bFF3Z1JUa3NsaFBNTDlITGpXM1RnNTF5MDlJd0MtaWtnUl8xNWd0LXhB?oc=5", "source_name": "Market source", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcEFMLXh0SlZzWkdHV1RaM3I5b2kxeF9Ub3k5XzNKSm1sd2JzaHhxemtmSFNucmkta2hfYVVzXzZxSGUtWkpJYUZmZHpTNWRqTzJHWE45dkpHZDk2N3lMcjlzcTdmZ0VmX0Q5Z3dSUlBmVlNrMmU1Y2MyamhUTkNCQjZPUHQwWWgxNGppcWVVS0xSbU5sUFFhZndhVXdLTmN4dW9n?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) \u2013 Here\u2019s Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQm54cEJXcjI3QzE4ZktJSzR1YjhpNUROWjZZNnV2aVRrbzhXY2VKSmlJMXBQOHR3a2FXbFFFTGlITFVtbzNfUG9CVzlPSEtnTG1lQkh5UkdhYkNNcmVubjk5VjQ2WlVYUUhxZ2EzOHlQa2Nsc1JaNFZjbWIxSVNPa3pfa19US1dkelJDZ0RQXzV4Zl91cjd4SGFndUFuNUF1S0k0?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron gMG drug cemdisiran clears FDA, EMA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPekhQeHZBSEYwbFFCWS1oMHZKWXhla1JxR2lHSzVFWjdaMlhZRWVDcTM0blNHem5GQ29VZkk5ejFBN0tIMFRpYk5feXQ2V1kzelc2NkR2M1VfM2FYeUd6aWQ3RVZ4OENjUDRBM0dCRlNGRm1KX19IMHhHY3QxWGEzMGJNUUlaSDRQU243Y2tFSVZpMTdnczJPSkFCMDlVcUNtSTB2UTlhQmlmdlVZZzQ1SlhJaDR3SWJfQVQ1a2VscmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNd1BMU1B1WmdmNnR1WGZOTjVhdWM4ODdKZWp4M21Ja0ZfVzlvMFhudmZoalVuTmRnNDBpanpkU1lBeFRyYU9QWURxaVhTZmJheDdvRFZiaGFEaHVXZE9aOURDdmFjaDVIYTI0WkRPSWxQbXVBeFo5M2hjaFFqU1hLdVVVQk1WTlJXQThXOEhKZHNfbVcxUmZTd0dVSW5QZVRKRHRWbUZRWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron (REGN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxONXV2V3Q5VUxkcXl0WUEtS2k3YWI0cklXLVhHcDhFbGRmQVY2Q0xqR2QzdFdPOG05NGR2amhDdzk3N1V1TnZIa0ltTkhGOVBPdHNpc0dicXMweV9HcnNza2M0VFZEeVJvcHpWZ2pRckJrdFVERTFKREQzNWl2ZUpwU09Ja3JUZ092Z1FGQTM5V1QtRWJBLWY0WEp6SFFpZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOSGVKTE1xU1kxX0hTQjUxMFhLWmVFWjlPNThQM3BFY0hUMWIxRmhMT1hwZFVhLTM4ai1vSUVERUNqcWxLaFZ4N0hocFRRMTk0TFNOREdWVDZIWmQ1ak1mLUl2bGxDVnBHRFZya0VxVGFOa3NqQWw3cG43WEdaSjhycDV4dGNUSUljZU1LZUxPd3BrU1BJbUdwMmN5WVVfZFNYV1R2d0hHRUxMSmVMUkk1S2p5SDRidXpTLWZMcTVEZGV1dUw4bU5QTm8yY0NBLV9ycXAwSEJ5UzQ5NzVTQjk3dkRmbXl2Mk54V0doVA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOeklDZm1TSWlCUXJiR240WUVXaGNETkF4QmQxZklXYWxHQmFudnpBMHVsem1BU0hCMzlQSzktZVNkajFpNlkxVUNrYU5lV1ZHbjdDckZiVG9TdVIxckpGcUlnMjJrWllPbkppVHZ5bUpMS3doMVRQYUctcFk1QWZsMVZGZ2R4VkZETzJyWU5TTXI5M0lmZkJEQjV4V0YyZEFwR09aekNIc2lvZw?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOZWREc0YxUmZLOGFDRmNUSGNQN0ROSXJXMzJvQlFueVJCdDg3U1VBUHFya0NfN18zN0hDQWY2eHhQLWZzMTdEdWdGcGZTUDZDX3RhV1gyR3dWSGkwbVh6aHl6Vnc3NzBvN1M0OUNDQUs0dUQzWTRZc1hkWjZlcjNnZEd2eUkxT3FZNzF2ajFCTjRwV3ZOc0gxb1hUbl9vUXcxS2FmVjdOWGM0TTJDRy1TdXhn?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron (REGN) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSmR4TDJDMmgzM3d2U24xR3kzemtiTGpJVDFqWllVZE1IZ09RVXBET0M3cGRqOEFCU3BkTktvSGhxRWtkUHRrWTZqS3NZeWF5X1VpXzZSYTgtNFRjTnZhZmZlM1E5Tl9GLXlsUnAxTE1jUEVwcFdKazU0RkU0eHpidEJ2U2FELUpTS3BSUnI0RWlsU1RxMjRId043aFVEdEE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: Dow, S&P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike\u2014 Regeneron Pharma, N", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxOT282X0t6enFXTWxTSkExeFBpd1d5ZmNxYVNFQnlxaUVCbGVQOUJZTTV0TW9NRVVWcjdMaDJYaGlLYl9nZ21IRkZVV1VYRzBwSjBVdHR5eGEwOC11RGFXSVNZU09INDVHb0E3UnpEWG9QemdHd0hra1htczl4bWdYdGphSTYzU2UxTTJWbmFrUmEzdzdIZWZrbmZ0Yl81OTFidm94MTB5VHJKWkpIZk9yd3luWU9lQm0xeWl6NXNISDB2RkFBNkJLY3dkZmZSNC1CZ2NrUXhQS2lnM0hTdWZrSFR6LXhSVllya0d1X1ZDRmVXQzNsSHlQbW9rNWxjQUt1ZE96eEJaTEVuWGhvanY4dXVpMjBfLWNac1B5Vk1POA?oc=5", "source_name": "Benzinga", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbW50aG5rWjFnY1Roa3ZuRTBnVDdnX2R4MjhnVU5Wc2VFX2JOX3dLLVBPOUFTbmxCOVBCdEluM1VfcFRFX05EUF9Nd3JsWVUzbVd1N3c1NE1Ma05JQkZIcklscExmaVRFTXRHME1sdTU3ZWhvU0xVdS1SZDgwVmoyT2E2Ui1iSUUwNHFIQ2haXzNza0luT2d2cmhRalh4RFpRcG5pY0Q3M2JvX2ZMcXoxcUlyYkFKNzE0dG1jMkVNR2oxNGc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRzloS29uSENaS2dldXhUQ2tldTY3MFZnT0Fva2VZSDZlT2l1MFUtUUF0akprT25VUDlPRGtYbkRCRTQ2dGdLR2Uwdzdkb28wNG9pVXU1M2kwNVVPQmhGYUZIODJ1WElBNHdNZ1Zxa2NwUGgzM0cxcWJKa1kyNVpFR1lPVmZmWGxvUlJj?oc=5", "source_name": "TradingKey", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPSE1iSmxGTDJfemxsYm9lUE5rSnlvVTdSOU0xY05va1hUT2RGSkZkb044TGZsZDVubFFhVnBvMFZ1MXZ3VllGWTNET1ZQMnZLZjFkc1k2NUQxSi1HSERoOWlNNTBrQWRxLTNqbGt4UFR4REZBUUZ0dmZ3b24zY2FvTkFaTjBTcDhQMEszZjdqQlpWbkE0TFZBVElvWlNZUkd6M3BJ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMmpYRHYzVWl4SjdvOGV5WW1PWkpYamtjbjJSVkZBZ2VhZDlHYWtFS2RvVWdxZWdKNUt0WC1lUXFEaGsyVWZaNm1jalEzam53T3ktQnFiNXVQOXFnSU1HaUVhSlQzSGxFWmVCUHJhUmoyTEdac2wwS1czdnR4M2ZDbUJ5XzlsZ3dU0gGOAUFVX3lxTE1NeGRic3UxeWRUY1ZLZm5GLV8zY1UwaGJLdldpQUpkUmhEX1VRM2loWVNIMkNoWVBmLVdoSWZsbUw5NmQ4VjZWMV9IR251S1o5TFplU1pzaG54TGg0VEg5NFBOVkhvOTYwbFljNlliQXotRS1WQ214STJtM1huVzBEWEdWeE9lTHpUcXJySXc?oc=5", "source_name": "CNBC", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron CEO Defends Pharma, Warns China Will \u2018Pass Us Right By\u2019 After Announcing Free Gene Therapy For Hearing Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZjVMTnpPY0J3TXRESVlaRWtyeGhTTHZOV2k2SkN4V3lWamtHZkQ4MUc4U0dBeHJTX2ZlSWVhUy1yZ3Z0U3pEbUZiRGluLWRUNHVvMnRnMGFSQ2l1cTdrU2stX0pzbDRMOTZyOFY1eENZeXAxdHpUbkZpZkN2aDloZi1JMlgyRm9paFhOUEt2R0liMk9BaWVGWkVieTBGaUVLdmlpSjNERV9jU1BqQ2lMMkg1RnFXX1pRNFNnakI4SW1WQjluS0NsLUtnV2xCbWtROXc?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron unveils latest 'most favored nation' drug pricing deal with White House", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOcHFnblRka0pjSWM4NWFyOEo2Q2gwd1hFUE92Rlgxbi1vMjhDZmdLSU03dlVPMmJRXzcyblpSOXJvdE80WVRvQUZPN09NYlQzV2hjd1NTQm85Z2VHZ3l1VTZOTFVVWFZhTXJoamQwZHlFSUVNT1JRdUJ4VVZIM0cwXzFVeXpLbG1lZ2ZndEpyQkJQaDBidFRKNnBxaXZkNF9qWjc5bTlhS1gzd3p2OVE?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Regeneron says it expects to avoid new US pharma tariffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdkhkdnpoYnBoTE9zSXZxeFFvM0dxT053bnQyMENyekwtX3hxbHFFV1l0Y2lGX09BNDhoQlNvc2VMRnFVUTFuaEo4X1VBbHBfZlhYX3prRWgyb1h2VTluVDN0S3dLVnJJTXNQc1J1ZHdIR24tajZ3N1QzWElwMGhvRlA4akNxa19VS0tDM1BDLVBxZDZZZFJYY0VQRi00SVlmbDBmcG1LM1ZGQndPbng3Yi1mVVh3aENYOFhxS19yaUhKYm8?oc=5", "source_name": "Reuters", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNYWptSHdpRjhGTll4aWRVa3FRcGxSaklOQ0dKRVJuN2FHTElkMEtCbXltNE1RbDRDTTB4VzVkWGJoWVNSV3l0RXJ1Wlo5RlotUFd6alZsVU55QkV3anRFZEp4YWlsd3VsTXlQV3U0eGxDRkFuTzA4N3Y1ZVBpQ1Q2Y2dPVktfbHFfdWxuRzdB?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPN2VfM3NEWVE4NDdjYXEwaGJncjVOZDFCbDlNUnZMZ1BYVmktLU9KZTlTS2dqNnB6TGpPRElLcmFVQVlGNi1KWVBYMHlQT0FPWWx5UlhXV2hPQUdCLVB5Uk1FV3FrbHQ4M3IwQmhIY3gyUVJGT0xNenpXUVZsN1luLUNzaU1HNGF4dC12MQ?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENERON PHARMACEUTICALS, INC. SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOelNVenhrakllM01qUmZrWkNaSmxNbXV2bm14ajNJN29fMlNHTWc5R0pnVV8wcnhneU9EbS1oeGE5bDk0d1J5LWR1eWhxT3puSjRXOVd0RXlINUtrQjFoNUZKQ3RTc2RtdkFtaGd4N0JfbzY5RjJvZi1CQ2lhUHFLVUstYUZZbEZaNHI5bVhmcHRQWDRLVmEyY2NybVoxOEpTZ1QtTGxQbjFrOTA?oc=5", "source_name": "TradingView", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPbm9XZ2dqcGJ2LU4yWG04dUpDajRXVHhSdkZDSWw4a0UyeFA5TGZqZ0luNTBIZ0NQLW52SU05aXNVanRBazZYanQ2Smlya0w5Um9VdUdYNE52bGdNUzNLbVd3Z0xDRTM2bVVRNlZ6aF9xRWREVzlfRnI0VDYzUy1EcjBNNHN4UC1aWUdPRjY0SnFhM0VNMVoyUTEtdnIxOUxXMjd5b05B?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQS0RDSzU5SFBvb3pVdWtXSlZqblp6UzdnUFRCdG5TZlNZd25taWotUHUwVmpPV0ZWblBPUEk5cGk5Qm1FWnhybGlKMnp5bjgyRENwM093cXlHNGJaLXV5dURXR1ZjcUJBTDRnNDdqZTFnOS1OY01qVGxzSXloMUtoNTB6ck02YnNCZUpIZVMzV3pYNXpZV3g4Sk9ON2UyTjN3SDBLRkZaVHZxRjVPblA3RElManhHVkJHa005Q1gzeTlDQnpfcW52bTVUcWFtaDBvSm1GeXc0eUZGYWotaTlhekZwblAxQnBUR2gwOW9WYm_SAfYBQVVfeXFMTlNOMjR3ZXd3M3BYV0s5TmRuNmlVbTZiN3R5SWQ5LWF1NFp4UTlyNTloY014RThDYmJLUy0wRDBZa2w2dkowZGxSRFBPcXdkNXNxQ3FWR1JIcFJWb2hGcmpVVkpVUWl2bjdoLWRsSllYRjNnazhCZ3Jjd092Z1Z4bWhmV004WENkSV81UEwzTXBTR0xmbGRKNTNEUUwzNnBYX0NBbm91UGFIODRwSkFEVlFxRTBkeWtlWEdLSWxyNm9TVGRyX2Y3Ry1VclZnZV9aaHFfcmpXSU12Z0wweWp5NzRYOXJpajdPUTN3UmVYR3BDc1R4UkFR?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?", "summary": "Regeneron Pharmaceuticals (REGN) recently experienced a clinical trial setback, causing its stock price to decline by almost 13% over 90 days, despite a 20.39% 1-year return. Analysts still view the stock as undervalued, with a fair value target of $833.31 against a current price", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-stumbled-in-a-trial-setback-i", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:54:59", "published_display": "15 Jul 2026 12:54", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "Vertex Pharmaceuticals (VRTX) is acquiring Crinetics Pharmaceuticals in a US$10 billion all-cash transaction, marking its entry into adrenal disease therapeutics. This acquisition includes atumelnant, a late-stage clinical drug candidate for congenital adrenal hyperplasia. The de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-vrtx-is-buying-crinetics-for-10-billion-to-enter-adre", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:51:29", "published_display": "15 Jul 2026 12:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease", "summary": "Alnylam Pharmaceuticals presented significant advancements in its neuroscience portfolio at AAIC 2026, focusing on RNAi therapeutics for neurological diseases. Key announcements include the initiation of a global Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer'", "url": "https://uk.finance.yahoo.com/news/alnylam-highlights-progress-neuroscience-programs-073000834.html", "source_name": "Market source", "published_at": "2026-07-15T07:45:34", "published_display": "15 Jul 2026 07:45", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQY3IwRDM1SGNON0J2T1R2aWRwLTFIV2h6QUt1R2ppbVA3Z1h5dXNuYWZxeHJ0dmJ0THBoVFJoVG1XTW5VNmRYSjAzcXlPVjdIMnA3dkt6ZVU2a3pvUGdyQmtwLWJKRUN5OWdEUVoyNGU4MndFMHdhUUE2RFVmZkFtMEpJdFlrdXlsSWkzVXBCTnZpUVh4VHBhRF9DY1RLSHVacHZSdmRUSmlUSjVIUVBLQ2xVQkduemM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T03:45:06+00:00", "published_display": "15 Jul 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day", "summary": "Regeneron Pharmaceuticals Inc. (REGN) saw its stock slide by 1.05% to $656.12, marking its third consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) rose 0.38% and the Dow Jones Industrial Average (DJIA) ros", "url": "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-outperforms-competitors-despite-losses-on-the-day-f2cdf7b8-58b39835bef2?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-14T23:08:47", "published_display": "14 Jul 2026 23:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab", "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that its medication dupilumab received FDA orphan drug designation, a status granted to drugs for rare diseases that offers benefits like tax credits and market exclusivity. This designation is a significant milestone, enhan", "url": "https://www.gurufocus.com/news/8958647/regeneron-regn-receives-fda-orphan-drug-designation-for-dupilumab", "source_name": "GuruFocus", "published_at": "2026-07-14T21:56:02", "published_display": "14 Jul 2026 21:56", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron stock holds firm as the focus shifts to the pipeline", "summary": "Regeneron Pharmaceuticals, Inc. (REGN) is a Nasdaq-listed biotech company focusing on a diversified drug portfolio and a late-stage pipeline. The company's business model generates revenue from marketed medicines and collaboration agreements, with its research platform centered o", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/regeneron-stock-holds-firm-as-the-focus-shifts-to-the-pipeline/69763731", "source_name": "Ad Hoc News", "published_at": "2026-07-14T06:14:19", "published_display": "14 Jul 2026 06:14", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes Regeneron Pharmaceuticals' (REGN) presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key highlights include strong double-digit growth in Q1 driven by core franchises, a robust pipeline with approximately 50 candidates, and", "url": "https://quartr.com/events/regeneron-pharmaceuticals-regn-goldman-sachs-47th-annual-global-healthcare-conference-2026_3g9vFpjs", "source_name": "Quartr", "published_at": "2026-07-14T05:38:59", "published_display": "14 Jul 2026 05:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vertex Pharmaceuticals (VRTX) A Bargain On Its Expanded CASGEVY Approval?", "summary": "Vertex Pharmaceuticals (VRTX) recently received expanded US approval for its gene therapy CASGEVY for children with sickle cell disease or beta thalassemia, influencing its stock performance. Despite a recent dip, the stock maintains long-term momentum and trades significantly be", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-a-bargain-on-its-expanded-cas", "source_name": "Simply Wall Street", "published_at": "2026-07-14T00:56:20", "published_display": "14 Jul 2026 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod \u2014 Drug Pricing Deal With White House To Be Announced Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOVVpIY2VFTkR2Mm42emFvcGxFRjNqMjh0bzZpak1SSmRFVGFNZllON2xtLW41ek4xWVNFYmhHVktjSGZua3A4UWpHb0lXS296ek9LbUhYQlM4YmdiQVpVVEN2aEhJUEF3OVVOcTRIRGpXZUFldWpiNXJPRnFUZy14TjhRa1g1ZWJ0LWpzRm0zTGEzeVpJUElDVzBVOUFGSnMySkxjeTQ0V3lGU2J0ZVU3bGZRUWJyX2VORkN1VlBNYkJYZXVua3Zv?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T22:36:29+00:00", "published_display": "13 Jul 2026 22:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron\u2019s (REGN) Investment Narrative?", "summary": "Regeneron Pharmaceuticals (REGN) recently experienced a setback with disappointing clinical trial results, raising concerns about its near-term pipeline productivity despite strong sales of Dupixent and Eylea and active share repurchases. This contrast has led to a shift in inves", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/did-disappointing-trial-data-amid-strong-dupixent-and-eylea/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-13T21:38:55", "published_display": "13 Jul 2026 21:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case.", "summary": "Incyte presents a clearer path for biotech investors seeking growth compared to Regeneron. While Regeneron manages complexities with its massive blockbusters and relies on pipeline faith, Incyte has raised its full-year guidance and is showing accelerating growth outside its main", "url": "https://www.trefis.com/stock/regn/articles/606839/own-regeneron-for-biotech-growth-incyte-is-making-its-case/2026-07-13", "source_name": "Trefis", "published_at": "2026-07-13T17:37:03", "published_display": "13 Jul 2026 17:37", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Regeneron stock", "summary": "Cantor Fitzgerald reiterated an Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750.00. The firm discussed the potential of Regeneron's pozelimab/cemdisiran treatment for retinal conditions, noting cautious optimism from a key opinion leader about its ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-regeneron-stock-93CH-4788459", "source_name": "Investing.com", "published_at": "2026-07-13T12:38:04", "published_display": "13 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Regeneron stock By Investing.com", "summary": "Cantor Fitzgerald has reaffirmed its Overweight rating on Regeneron Pharmaceuticals Inc. with a price target of $750, despite previously lowering it from $785 due to concerns about Eylea HD/SD and Dupixent performance. The firm's positive outlook is based on Regeneron's pozelimab", "url": "https://ca.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-overweight-on-regeneron-stock-93CH-4731128", "source_name": "Investing.com Canada", "published_at": "2026-07-13T12:35:51", "published_display": "13 Jul 2026 12:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2", "summary": "Longleaf Partners Fund's Q2 2026 investor letter noted that Regeneron Pharmaceuticals (REGN) was a detractor due to disappointing trial results for one of its pipeline drugs. While Dupixent's performance exceeded expectations and Eylea stabilized, the company's \"one out of three\"", "url": "https://finance.yahoo.com/healthcare/articles/disappointing-trial-results-hurt-regeneron-143335859.html", "source_name": "Market source", "published_at": "2026-07-13T10:33:00", "published_display": "13 Jul 2026 10:33", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Cites Medtronic Ruling In Amgen Bundling Case", "summary": "Regeneron has invoked a recent Medtronic ruling in a California federal court to bolster its $407 million victory against Amgen. This action was taken in a Delaware federal court, where Regeneron is seeking to preserve its win in a case concerning the bundling of cholesterol drug", "url": "https://www.law360.com/healthcare-authority/deals-corporate-governance/articles/2498786/regeneron-cites-medtronic-ruling-in-amgen-bundling-case", "source_name": "Law360", "published_at": "2026-07-10T01:09:37", "published_display": "10 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGN Maintained by Piper Sandler -- Price Target Lowered to $854", "summary": "Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals (REGN) but slightly lowered its price target from $855 to $854. Despite this minor adjustment, the company is considered 26.5% undervalued according to GuruFocus's GF Value\u2122 and holds a strong GF Score", "url": "https://www.gurufocus.com/news/8951888/regn-maintained-by-piper-sandler-price-target-lowered-to-854", "source_name": "GuruFocus", "published_at": "2026-07-09T16:22:34", "published_display": "09 Jul 2026 16:22", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855", "summary": "Piper Sandler has slightly decreased its price target for Regeneron Pharmaceuticals (REGN) from $855 to $854. The firm maintained an Overweight rating on the stock. This adjustment reflects a minor change in Piper Sandler's valuation outlook for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/72711738/piper-sandler-adjusts-price-target-on-regeneron-pharmaceuticals-to-854", "source_name": "Moomoo", "published_at": "2026-07-09T15:38:38", "published_display": "09 Jul 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730", "summary": "Morgan Stanley has reiterated its Hold rating on Regeneron Pharmaceuticals (REGN.US) but decided to lower its target price for the stock to $730. This adjustment in the target price suggests a revised outlook by the analyst firm on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72655814/morgan-stanley-maintains-regeneron-pharmaceuticals-regnus-with-hold-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-09T08:38:55", "published_display": "09 Jul 2026 08:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating", "summary": "Morgan Stanley has lowered its price target for Regeneron Pharmaceuticals (NASDAQ: REGN) to $730 from $788, while maintaining an Equalweight rating on the stock. This adjustment comes after a review of the company's financial outlook.", "url": "https://www.moomoo.com/news/post/72642560/morgan-stanley-adjusts-price-target-regeneron-pharmaceuticals-to-730-from", "source_name": "Moomoo", "published_at": "2026-07-09T03:08:40", "published_display": "09 Jul 2026 03:08", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGN Maintained by Morgan Stanley -- Price Target Lowered to $73", "summary": "Morgan Stanley has maintained an Equal-Weight rating on Regeneron Pharmaceuticals (REGN) but lowered its price target from $788 to $730, citing a cautious outlook. Despite this, GuruFocus indicates REGN is undervalued by 26.5% with a strong GF Score\u2122 of 78/100, driven by excellen", "url": "https://www.gurufocus.com/news/8950280/regn-maintained-by-morgan-stanley-price-target-lowered-to-730", "source_name": "GuruFocus", "published_at": "2026-07-08T22:45:37", "published_display": "08 Jul 2026 22:45", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors", "summary": "Regeneron Pharmaceuticals Inc. (REGN) stock declined by 1.97% to $662.88 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also fell. The company's stock closed 19.27% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-underperforms-wednesday-when-compared-to-competitors-e2608ad2-a4264797bd51", "source_name": "MarketWatch", "published_at": "2026-07-08T20:43:00", "published_display": "08 Jul 2026 20:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar", "summary": "Regeneron Pharmaceuticals Inc. successfully moved to dismiss Amgen Inc.'s fraud-based defenses and certain antitrust claims concerning proposed Eylea biosimilars. However, a federal judge allowed Amgen to continue arguing that Regeneron delayed too long in pursuing a specific pat", "url": "https://news.bloomberglaw.com/ip-law/regeneron-narrows-amgen-challenges-in-case-over-eylea-biosimilar", "source_name": "Bloomberg Law News", "published_at": "2026-07-08T15:59:00", "published_display": "08 Jul 2026 15:59", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals balances growth prospects as a major biotech player. The company continues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQSWdtUjBMUTduUTZHSFBuVVQwcnRRR3h2VWEtVHZ0NEpPUVZBZFdfd3FMd2Z5bDB3dnRpdzdtMnFlTkZyMEx2OFRwSXNRRUwyV2pVMnVzbW4yOHFBdWphZnBBQnNqVWdGMFRZVDJXV2NZQUpxUjJ5S0U0MlpxelBzV1BqcEFGdnZ3SEJjS3cxbndFbjBqNVNGb2pheUoxMjNaajlJQnoxbU5faERzLV9JT1FkYlpUUnlHN1ZFdWRCVTF2TkRMWmd6YQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQaGstaFdQa3pfYzJ1SFBhZ3ltbUxXS0IxVkhvc2xCTVFrdDU5dVVZaUZDZnpnNm85Y1NrVFhDc0xETEYzMkZNNmNzMHBDdTdvUDlQdklibFN4N2hwLTAySXVHUkRYcFJOWm55S3dwSERMWlNVTE1SVHAtWWVoZUYweHlvZ2IwM2FZQ1R5b3NmTFQwdUpuc09tZ0lTR0FDVWo1LVVB?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals profile and stock context for US investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPaFVuYnJ4MXRVaXIyWHUxdnBPRGljVDZUa1VKb0t6M1U3MmM4SkFoRURQMHRCS2M3VmhZTkdTMVpNM25oNklmQS0tYnpKRlMtY2drclIxQ01Kdkx3NEREM0hQZ2dCNFZMaGkwTlk2c2JpU00xZEFZVWdVaGw5QnA5MERvUEZjYU9DZ0dBc0RrN1JMa1RxQ09sSC1QbXJTQUlfVm1Zc19FOEFkbkJYZXk5b05lcm4wNHpzSlM1VElMb3Z0QjNncXc?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:37:25+00:00", "published_display": "07 Jul 2026 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOSFAzZjROeDlMbllNcVBfbmIwMlpNUXdhU2dCaTZUa2VVODZZeW5UeDZHcW5HdFdzak00Xzk2RF95UnpfazM4N0NvY3FCTThCSVZqblJvenloN1BKRE1NcGNQenVzcnVZU2ZtclUwYjg3TEFncXI1OFdKSm40bFF3Z1JUa3NsaFBNTDlITGpXM1RnNTF5MDlJd0MtaWtnUl8xNWd0LXhB?oc=5", "source_name": "Market source", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcEFMLXh0SlZzWkdHV1RaM3I5b2kxeF9Ub3k5XzNKSm1sd2JzaHhxemtmSFNucmkta2hfYVVzXzZxSGUtWkpJYUZmZHpTNWRqTzJHWE45dkpHZDk2N3lMcjlzcTdmZ0VmX0Q5Z3dSUlBmVlNrMmU1Y2MyamhUTkNCQjZPUHQwWWgxNGppcWVVS0xSbU5sUFFhZndhVXdLTmN4dW9n?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) \u2013 Here\u2019s Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQm54cEJXcjI3QzE4ZktJSzR1YjhpNUROWjZZNnV2aVRrbzhXY2VKSmlJMXBQOHR3a2FXbFFFTGlITFVtbzNfUG9CVzlPSEtnTG1lQkh5UkdhYkNNcmVubjk5VjQ2WlVYUUhxZ2EzOHlQa2Nsc1JaNFZjbWIxSVNPa3pfa19US1dkelJDZ0RQXzV4Zl91cjd4SGFndUFuNUF1S0k0?oc=5", "source_name": "Market source", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron gMG drug cemdisiran clears FDA, EMA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPekhQeHZBSEYwbFFCWS1oMHZKWXhla1JxR2lHSzVFWjdaMlhZRWVDcTM0blNHem5GQ29VZkk5ejFBN0tIMFRpYk5feXQ2V1kzelc2NkR2M1VfM2FYeUd6aWQ3RVZ4OENjUDRBM0dCRlNGRm1KX19IMHhHY3QxWGEzMGJNUUlaSDRQU243Y2tFSVZpMTdnczJPSkFCMDlVcUNtSTB2UTlhQmlmdlVZZzQ1SlhJaDR3SWJfQVQ1a2VscmY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNd1BMU1B1WmdmNnR1WGZOTjVhdWM4ODdKZWp4M21Ja0ZfVzlvMFhudmZoalVuTmRnNDBpanpkU1lBeFRyYU9QWURxaVhTZmJheDdvRFZiaGFEaHVXZE9aOURDdmFjaDVIYTI0WkRPSWxQbXVBeFo5M2hjaFFqU1hLdVVVQk1WTlJXQThXOEhKZHNfbVcxUmZTd0dVSW5QZVRKRHRWbUZRWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron (REGN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxONXV2V3Q5VUxkcXl0WUEtS2k3YWI0cklXLVhHcDhFbGRmQVY2Q0xqR2QzdFdPOG05NGR2amhDdzk3N1V1TnZIa0ltTkhGOVBPdHNpc0dicXMweV9HcnNza2M0VFZEeVJvcHpWZ2pRckJrdFVERTFKREQzNWl2ZUpwU09Ja3JUZ092Z1FGQTM5V1QtRWJBLWY0WEp6SFFpZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOSGVKTE1xU1kxX0hTQjUxMFhLWmVFWjlPNThQM3BFY0hUMWIxRmhMT1hwZFVhLTM4ai1vSUVERUNqcWxLaFZ4N0hocFRRMTk0TFNOREdWVDZIWmQ1ak1mLUl2bGxDVnBHRFZya0VxVGFOa3NqQWw3cG43WEdaSjhycDV4dGNUSUljZU1LZUxPd3BrU1BJbUdwMmN5WVVfZFNYV1R2d0hHRUxMSmVMUkk1S2p5SDRidXpTLWZMcTVEZGV1dUw4bU5QTm8yY0NBLV9ycXAwSEJ5UzQ5NzVTQjk3dkRmbXl2Mk54V0doVA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOeklDZm1TSWlCUXJiR240WUVXaGNETkF4QmQxZklXYWxHQmFudnpBMHVsem1BU0hCMzlQSzktZVNkajFpNlkxVUNrYU5lV1ZHbjdDckZiVG9TdVIxckpGcUlnMjJrWllPbkppVHZ5bUpMS3doMVRQYUctcFk1QWZsMVZGZ2R4VkZETzJyWU5TTXI5M0lmZkJEQjV4V0YyZEFwR09aekNIc2lvZw?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOZWREc0YxUmZLOGFDRmNUSGNQN0ROSXJXMzJvQlFueVJCdDg3U1VBUHFya0NfN18zN0hDQWY2eHhQLWZzMTdEdWdGcGZTUDZDX3RhV1gyR3dWSGkwbVh6aHl6Vnc3NzBvN1M0OUNDQUs0dUQzWTRZc1hkWjZlcjNnZEd2eUkxT3FZNzF2ajFCTjRwV3ZOc0gxb1hUbl9vUXcxS2FmVjdOWGM0TTJDRy1TdXhn?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron (REGN) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSmR4TDJDMmgzM3d2U24xR3kzemtiTGpJVDFqWllVZE1IZ09RVXBET0M3cGRqOEFCU3BkTktvSGhxRWtkUHRrWTZqS3NZeWF5X1VpXzZSYTgtNFRjTnZhZmZlM1E5Tl9GLXlsUnAxTE1jUEVwcFdKazU0RkU0eHpidEJ2U2FELUpTS3BSUnI0RWlsU1RxMjRId043aFVEdEE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: Dow, S&P 500, Nasdaq Futures Drop After UAE Nuclear Plant Strike\u2014 Regeneron Pharma, N", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxOT282X0t6enFXTWxTSkExeFBpd1d5ZmNxYVNFQnlxaUVCbGVQOUJZTTV0TW9NRVVWcjdMaDJYaGlLYl9nZ21IRkZVV1VYRzBwSjBVdHR5eGEwOC11RGFXSVNZU09INDVHb0E3UnpEWG9QemdHd0hra1htczl4bWdYdGphSTYzU2UxTTJWbmFrUmEzdzdIZWZrbmZ0Yl81OTFidm94MTB5VHJKWkpIZk9yd3luWU9lQm0xeWl6NXNISDB2RkFBNkJLY3dkZmZSNC1CZ2NrUXhQS2lnM0hTdWZrSFR6LXhSVllya0d1X1ZDRmVXQzNsSHlQbW9rNWxjQUt1ZE96eEJaTEVuWGhvanY4dXVpMjBfLWNac1B5Vk1POA?oc=5", "source_name": "Benzinga", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbW50aG5rWjFnY1Roa3ZuRTBnVDdnX2R4MjhnVU5Wc2VFX2JOX3dLLVBPOUFTbmxCOVBCdEluM1VfcFRFX05EUF9Nd3JsWVUzbVd1N3c1NE1Ma05JQkZIcklscExmaVRFTXRHME1sdTU3ZWhvU0xVdS1SZDgwVmoyT2E2Ui1iSUUwNHFIQ2haXzNza0luT2d2cmhRalh4RFpRcG5pY0Q3M2JvX2ZMcXoxcUlyYkFKNzE0dG1jMkVNR2oxNGc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRzloS29uSENaS2dldXhUQ2tldTY3MFZnT0Fva2VZSDZlT2l1MFUtUUF0akprT25VUDlPRGtYbkRCRTQ2dGdLR2Uwdzdkb28wNG9pVXU1M2kwNVVPQmhGYUZIODJ1WElBNHdNZ1Zxa2NwUGgzM0cxcWJKa1kyNVpFR1lPVmZmWGxvUlJj?oc=5", "source_name": "TradingKey", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPSE1iSmxGTDJfemxsYm9lUE5rSnlvVTdSOU0xY05va1hUT2RGSkZkb044TGZsZDVubFFhVnBvMFZ1MXZ3VllGWTNET1ZQMnZLZjFkc1k2NUQxSi1HSERoOWlNNTBrQWRxLTNqbGt4UFR4REZBUUZ0dmZ3b24zY2FvTkFaTjBTcDhQMEszZjdqQlpWbkE0TFZBVElvWlNZUkd6M3BJ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMmpYRHYzVWl4SjdvOGV5WW1PWkpYamtjbjJSVkZBZ2VhZDlHYWtFS2RvVWdxZWdKNUt0WC1lUXFEaGsyVWZaNm1jalEzam53T3ktQnFiNXVQOXFnSU1HaUVhSlQzSGxFWmVCUHJhUmoyTEdac2wwS1czdnR4M2ZDbUJ5XzlsZ3dU0gGOAUFVX3lxTE1NeGRic3UxeWRUY1ZLZm5GLV8zY1UwaGJLdldpQUpkUmhEX1VRM2loWVNIMkNoWVBmLVdoSWZsbUw5NmQ4VjZWMV9IR251S1o5TFplU1pzaG54TGg0VEg5NFBOVkhvOTYwbFljNlliQXotRS1WQ214STJtM1huVzBEWEdWeE9lTHpUcXJySXc?oc=5", "source_name": "CNBC", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron CEO Defends Pharma, Warns China Will \u2018Pass Us Right By\u2019 After Announcing Free Gene Therapy For Hearing Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZjVMTnpPY0J3TXRESVlaRWtyeGhTTHZOV2k2SkN4V3lWamtHZkQ4MUc4U0dBeHJTX2ZlSWVhUy1yZ3Z0U3pEbUZiRGluLWRUNHVvMnRnMGFSQ2l1cTdrU2stX0pzbDRMOTZyOFY1eENZeXAxdHpUbkZpZkN2aDloZi1JMlgyRm9paFhOUEt2R0liMk9BaWVGWkVieTBGaUVLdmlpSjNERV9jU1BqQ2lMMkg1RnFXX1pRNFNnakI4SW1WQjluS0NsLUtnV2xCbWtROXc?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron unveils latest 'most favored nation' drug pricing deal with White House", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOcHFnblRka0pjSWM4NWFyOEo2Q2gwd1hFUE92Rlgxbi1vMjhDZmdLSU03dlVPMmJRXzcyblpSOXJvdE80WVRvQUZPN09NYlQzV2hjd1NTQm85Z2VHZ3l1VTZOTFVVWFZhTXJoamQwZHlFSUVNT1JRdUJ4VVZIM0cwXzFVeXpLbG1lZ2ZndEpyQkJQaDBidFRKNnBxaXZkNF9qWjc5bTlhS1gzd3p2OVE?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron says it expects to avoid new US pharma tariffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdkhkdnpoYnBoTE9zSXZxeFFvM0dxT053bnQyMENyekwtX3hxbHFFV1l0Y2lGX09BNDhoQlNvc2VMRnFVUTFuaEo4X1VBbHBfZlhYX3prRWgyb1h2VTluVDN0S3dLVnJJTXNQc1J1ZHdIR24tajZ3N1QzWElwMGhvRlA4akNxa19VS0tDM1BDLVBxZDZZZFJYY0VQRi00SVlmbDBmcG1LM1ZGQndPbng3Yi1mVVh3aENYOFhxS19yaUhKYm8?oc=5", "source_name": "Reuters", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNYWptSHdpRjhGTll4aWRVa3FRcGxSaklOQ0dKRVJuN2FHTElkMEtCbXltNE1RbDRDTTB4VzVkWGJoWVNSV3l0RXJ1Wlo5RlotUFd6alZsVU55QkV3anRFZEp4YWlsd3VsTXlQV3U0eGxDRkFuTzA4N3Y1ZVBpQ1Q2Y2dPVktfbHFfdWxuRzdB?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPN2VfM3NEWVE4NDdjYXEwaGJncjVOZDFCbDlNUnZMZ1BYVmktLU9KZTlTS2dqNnB6TGpPRElLcmFVQVlGNi1KWVBYMHlQT0FPWWx5UlhXV2hPQUdCLVB5Uk1FV3FrbHQ4M3IwQmhIY3gyUVJGT0xNenpXUVZsN1luLUNzaU1HNGF4dC12MQ?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENERON PHARMACEUTICALS, INC. SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOelNVenhrakllM01qUmZrWkNaSmxNbXV2bm14ajNJN29fMlNHTWc5R0pnVV8wcnhneU9EbS1oeGE5bDk0d1J5LWR1eWhxT3puSjRXOVd0RXlINUtrQjFoNUZKQ3RTc2RtdkFtaGd4N0JfbzY5RjJvZi1CQ2lhUHFLVUstYUZZbEZaNHI5bVhmcHRQWDRLVmEyY2NybVoxOEpTZ1QtTGxQbjFrOTA?oc=5", "source_name": "TradingView", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPbm9XZ2dqcGJ2LU4yWG04dUpDajRXVHhSdkZDSWw4a0UyeFA5TGZqZ0luNTBIZ0NQLW52SU05aXNVanRBazZYanQ2Smlya0w5Um9VdUdYNE52bGdNUzNLbVd3Z0xDRTM2bVVRNlZ6aF9xRWREVzlfRnI0VDYzUy1EcjBNNHN4UC1aWUdPRjY0SnFhM0VNMVoyUTEtdnIxOUxXMjd5b05B?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQS0RDSzU5SFBvb3pVdWtXSlZqblp6UzdnUFRCdG5TZlNZd25taWotUHUwVmpPV0ZWblBPUEk5cGk5Qm1FWnhybGlKMnp5bjgyRENwM093cXlHNGJaLXV5dURXR1ZjcUJBTDRnNDdqZTFnOS1OY01qVGxzSXloMUtoNTB6ck02YnNCZUpIZVMzV3pYNXpZV3g4Sk9ON2UyTjN3SDBLRkZaVHZxRjVPblA3RElManhHVkJHa005Q1gzeTlDQnpfcW52bTVUcWFtaDBvSm1GeXc0eUZGYWotaTlhekZwblAxQnBUR2gwOW9WYm_SAfYBQVVfeXFMTlNOMjR3ZXd3M3BYV0s5TmRuNmlVbTZiN3R5SWQ5LWF1NFp4UTlyNTloY014RThDYmJLUy0wRDBZa2w2dkowZGxSRFBPcXdkNXNxQ3FWR1JIcFJWb2hGcmpVVkpVUWl2bjdoLWRsSllYRjNnazhCZ3Jjd092Z1Z4bWhmV004WENkSV81UEwzTXBTR0xmbGRKNTNEUUwzNnBYX0NBbm91UGFIODRwSkFEVlFxRTBkeWtlWEdLSWxyNm9TVGRyX2Y3Ry1VclZnZV9aaHFfcmpXSU12Z0wweWp5NzRYOXJpajdPUTN3UmVYR3BDc1R4UkFR?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQWkRNNFR4Vm03V3ZVUEp3dW5hZUVfbjQ4V3QyNXJ1Y212X05TWFpRdEJxcnlFcVFkLVluZnpTWmVQSjBLUHJ6ZWhmdHQ4OWJiY2VmNEZ6RjYzVzUwQTlfVC1MamdRSk9lcmpqaFZjR05Yc1RRcjF1bDg3dktpVWxqQUpiVXFoWGJNV2MtMEkwajhROVhSZldRcmpPV0VLTG9TUkd0TUd2QU41RTRRWHBmQXJNWFpDWjV0RVJVNmZ3RHljdTR2bUlHMTg4TFpPMEFyQkNjajFYVEN2SWZxWE8wUEpIbGVlUGgwN3IyMFp4MkTSAfYBQVVfeXFMUEdTNklKZmRNQ3AxRUpZNHV3cnVmcWNCSlA3U3pOU2g4aV9ybkVZZDlwU0kwLXdWbFRRRlNmeUJWZ3hSUnB1OF9ZRTYyNzVUM25ZUWlSb2JjTEtLdnJrRVBER04wTVlMaUpKVUhXQXI2WlJBd3lHd0hPWTVfTW1EZXotTllaVkpseTR2ekg1QXdwT2lXUmVjWGpoTXQtZUx2aUJxSXVRVlptQUkyeS0zVmthWXdjNnBwSWpzYWFZV18xV25QbFcxMGg3QmxlRERrZXpPT2VsU1owbHpyRlNKeFpiZ3lFYmttdjlkWXdpV0FsTFVGTklB?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 108, "total_relevant": 60, "sentiment_summary": {"positive": 19, "negative": 15, "neutral": 26, "score": 51, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.45, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.29, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.45, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}], "positive_events": 19, "negative_events": 15}, "market_context": {"has_market_context": true, "latest_close": 664.52, "latest_week": "2026-07-10", "one_week_move": 1.6, "four_week_move": 8.6, "twelve_week_move": -11.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.946436, "market_dynamics_buy_signal": false, "relative_strength": -15.887692, "fair_value_gap": -14.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0753, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.6% over one week, +8.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "simplywall.st", "count": 6}, {"label": "Simply Wall Street", "count": 4}, {"label": "GuruFocus", "count": 4}, {"label": "Ad Hoc News", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "MarketWatch", "count": 2}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 10}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.6% over one week, +8.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?"}], "updated_at": "2026-07-16T12:47:28.506154+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}